type I diabetes

[AVM Biotechnology, LLC (Business Wire)] AVM Biotechnology, LLC, announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease will allow the company to pursue additional research in the use of AVM0703 as a monotherapy and combination therapy to reverse recent onset and established Type 1 Diabetes.

[Frontiers in Immunology] The authors used multiplex immunofluorescence imaging analysis to characterize MDA5 expression and distribution in pancreatic tissues obtained from 22 organ donors.

[JDRF, Inc. (BioSpace, Inc.)] JDRF, the leading global type 1 diabetes research and advocacy organization, announces a new collaboration with leading diabetes, advocacy, and healthcare partners to support a newly established insulin-centered project from Civica Inc.

[Nature Metabolism] Scientists provided a single-cell atlas of pancreatic islets of 24 type 1 diabetes, autoantibody-positive and nondiabetic organ donors across multiple quantitative modalities including ~80,000 cells using single-cell transcriptomics, ~7,000,000 cells using cytometry by time of flight and ~1,000,000 cells using in situ imaging mass cytometry.

[CRISPR Therapeutics] CRISPR Therapeutics and ViaCyte, Inc. announced the first patient has been dosed in the Phase I clinical trial of VCTX210 for the treatment of type I diabetes.

[Nature Communications] Scientists showed that the death receptor TMEM219 was expressed on pancreatic beta cells and that signaling through its ligand insulin-like growth factor binding protein 3 (IGFBP3) led to beta cell loss and dysfunction.